• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sempra Appoints Jennifer M. Kirk to Board of Directors

    6/20/24 4:15:00 PM ET
    $MDT
    $SRE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Natural Gas Distribution
    Utilities
    Get the next $MDT alert in real time by email

    SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry.

    Jennifer M. Kirk

    "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infrastructure company," said Jeffrey W. Martin, Sempra chairman and CEO. "Our board of directors embody a diverse set of skills, experiences and viewpoints that help guide Sempra's corporate strategy and overall business success. Jennifer's strong accounting and finance experience, coupled with her understanding of the energy business, will be a great complement to the board as we advance our corporate strategy and oversee financial discipline, risk management and ethical practices."

    Before joining Medtronic, Kirk, 49, worked at Occidental Petroleum Corporation for more than two decades, serving in roles of increasing responsibility, including senior vice president of integration and value capture, and vice president, controller and principal accounting officer.

    Kirk serves on the board of directors of Republic Services, where she is chair of the audit committee. She holds a bachelor's degree in economics from UC Santa Barbara and a master's degree in business administration from California State University, Bakersfield.

    With the appointment of Kirk, Sempra will have 10 directors with three having been newly elected over the past five years, reflecting the company's commitment to periodic board refreshment to ensure fresh and diverse perspectives are present in the boardroom. Kirk will serve on the board's audit committee and the safety, sustainability and technology committee.

    About Sempra

    Sempra (NYSE:SRE) is a leading North American energy infrastructure company focused on delivering energy to nearly 40 million consumers. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving the energy resilience of some of the world's most significant economic markets, including California, Texas, Mexico and global energy markets. The company is recognized as a leader in sustainable business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in the Dow Jones Sustainability Index North America and in The Wall Street Journal's Best Managed Companies. More information about Sempra is available at sempra.com and on social media @Sempra.

     

    Sempra Logo (PRNewsfoto/Sempra)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sempra-appoints-jennifer-m-kirk-to-board-of-directors-302177421.html

    SOURCE Sempra

    Get the next $MDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT
    $SRE

    CompanyDatePrice TargetRatingAnalyst
    Medtronic plc.
    $MDT
    11/19/2025$111.00Sell → Neutral
    Goldman
    DBA Sempra
    $SRE
    11/14/2025Neutral → Buy
    Goldman
    DBA Sempra
    $SRE
    10/28/2025$115.00Overweight
    Wells Fargo
    DBA Sempra
    $SRE
    10/22/2025$106.00Buy
    BTIG Research
    DBA Sempra
    $SRE
    10/20/2025$101.00Equal Weight → Overweight
    Barclays
    DBA Sempra
    $SRE
    10/7/2025$105.00Outperform
    Evercore ISI
    Medtronic plc.
    $MDT
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    Medtronic plc.
    $MDT
    6/16/2025$110.00Outperform
    Leerink Partners
    More analyst ratings

    $MDT
    $SRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed

    GALWAY, Ireland, Dec. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Diabetes business, which as previously announced will operate under the name MiniMed, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected to be completed through a series of capital markets transactions, with a preferred path of an IPO and subsequent split-off.  MiniMed intends to apply to have its common stock listed on the Nasdaq Global Select Market under the symbol MMED. The number of shares to be off

    12/19/25 4:20:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    IFM Investors Launches Texas-Based Mobius Renewables, a Global Low Carbon Fuels Platform

    IFM Investors ("IFM") today announced the formation of Mobius Renewables (the "Company"), a new global, vertically integrated low carbon fuels platform established to accelerate the development, production, distribution and commercialization of biomethane at scale across North America and Europe. Cynthia Walker has been appointed as President and CEO of the Company which will be headquartered in Houston, Texas. The Company will unite, under the leadership of Ms. Walker, IFM's existing platform GreenGasUSA, with planned acquisitions of operating biomethane facilities, and development opportunities originated by Mobius Fuels. The Company is expected to have over 5.5 million MMBtu per year of

    12/17/25 10:00:00 AM ET
    $CHRD
    $FLOC
    $OXY
    Oil & Gas Production
    Energy
    Oil and Gas Field Machinery
    Consumer Discretionary

    AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management

    12/12/25 9:49:00 AM ET
    $ABT
    $CBLL
    $HTFL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $MDT
    $SRE
    SEC Filings

    View All

    DBA Sempra filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SEMPRA (0001032208) (Filer)

    12/19/25 5:22:25 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.

    SCHEDULE 13G/A - Medtronic plc (0001613103) (Subject)

    12/3/25 11:20:42 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form IRANNOTICE filed by Medtronic plc.

    IRANNOTICE - Medtronic plc (0001613103) (Filer)

    11/25/25 4:19:12 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $SRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medtronic upgraded by Goldman with a new price target

    Goldman upgraded Medtronic from Sell to Neutral and set a new price target of $111.00

    11/19/25 8:47:22 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sempra Energy upgraded by Goldman

    Goldman upgraded Sempra Energy from Neutral to Buy

    11/14/25 10:23:31 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Wells Fargo initiated coverage on Sempra Energy with a new price target

    Wells Fargo initiated coverage of Sempra Energy with a rating of Overweight and set a new price target of $115.00

    10/28/25 8:19:49 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Ferrero Pablo bought $184,496 worth of shares (2,600 units at $70.96), increasing direct ownership by 20% to 15,649 units (SEC Form 4)

    4 - SEMPRA (0001032208) (Issuer)

    3/17/25 9:10:57 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Director Conesa Andres bought $100,156 worth of shares (1,400 units at $71.54), increasing direct ownership by 7% to 21,668 units (SEC Form 4)

    4 - SEMPRA (0001032208) (Issuer)

    3/17/25 9:10:19 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Pres Neuroscience Wall Brett A. covered exercise/tax liability with 439 units of Ordinary Shares, decreasing direct ownership by 0.80% to 54,749 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    12/17/25 4:18:48 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,371 units of Ordinary Shares, decreasing direct ownership by 3% to 50,818 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    12/17/25 4:18:25 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chairman and CEO Martha Geoffrey covered exercise/tax liability with 1,564 units of Ordinary Shares, decreasing direct ownership by 0.63% to 246,393 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    12/17/25 4:17:05 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $SRE
    Financials

    Live finance-specific insights

    View All

    Medtronic announces cash dividend for third quarter of fiscal year 2026

    GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

    12/4/25 4:32:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SoCalGas Declares Preferred Dividends

    LOS ANGELES, Nov. 18, 2025 /PRNewswire/ -- The board of directors of Southern California Gas Company (SoCalGas) has declared regular quarterly dividends for the preferred series stock of the company as follows: SoCalGas: Preferred Stock    $0.375 per share Preferred Stock, Series A $0.375 per share The dividends are payable on January 15, 2026, to shareholders of record on December 10, 2025. About SoCalGas SoCalGas is the largest gas distribution utility in the United States, serving more than 21 million consumers across approximately 24,000 square miles of Central and Southern California. Our mission is: Safe, Reliable, and Affordable energy delivery today. Ready for tomorrow. SoCalGas is a

    11/18/25 1:36:00 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum

    Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points above guidance midpointGAAP diluted EPS of $1.07 increased 8%; non-GAAP diluted EPS of $1.36 increased 8%, above guidanceRaising FY26 guidance: 5.5% organic revenue growth, $5.62-$5.66 adjusted

    11/18/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $SRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DBA Sempra

    SC 13G - SEMPRA (0001032208) (Subject)

    11/8/24 10:52:39 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by DBA Sempra (Amendment)

    SC 13G/A - SEMPRA (0001032208) (Subject)

    2/13/24 4:56:00 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Kayne Anderson Energy Infrastructure Fund Announces Appointment of New Independent Directors

    HOUSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the "Company" or "KYN") announced today the appointments of Holli C. Ladhani and Michael N. Mears as independent directors of the Company, effective immediately. Following the retirements of Anne K. Costin and Albert L. Richey earlier this year, the appointments of Ms. Ladhani and Mr. Mears return the Company's Board to eight members, seven of whom are independent. Holli C. Ladhani is an experienced executive and board director in the energy, chemicals, power, and infrastructure sectors. Ms. Ladhani most recently served as President, Chief Executive Officer, and a member of the board of directors of

    5/27/25 4:15:00 PM ET
    $DVN
    $KYN
    $PWR
    Oil & Gas Production
    Energy
    Finance/Investors Services
    Finance